Kymab has raised $100 million (€94 million) to fund the advance of its lead candidates into the clinic. The Series C round, which attracted new Chinese…

Let’s be honest, 2016 was a mess of year, and one that many of us will be happy to see the back of. It saw the loss of a series of beloved actors, actresses…

Motif Bio has put together a financing package to give it the money to wrap up a Phase III trial of its antibiotic iclaprim.

New York-based biotech Syntimmune has gained biopharma and VC veteran David de Graaf as its new president and CEO as the company gains the final $8 million…

In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from…

An entrepreneur who made his fortune building a $14 billion tech company is setting up a life science venture capital fund.

A combination of lower corporate taxes, a sense that deregulation for meds is coming and pricing issues will be dropped, bumped-up stocks and an influx of…

Evotec and the University of Oxford have teamed up to bridge the gap between academic research and industry.

Venture Capital